Clinical Outcomes improvement of refractory Obsessive compulsive disorder by use Olanazapine

الملخص

More than half of the patients with obsessive- compulsive disorder(OCD) remain unimproved by Serotonin-Reuptake inhibitors(SSRI). objective of this study was to examine whether addition of atypical antipsychotic (olanzapine ) to Sertraline is useful for patients with OCD who do not respond to SSRI monotherapy.
1. According to (DSM IV-TR criteria) , 20 patients are diagnosed asOCD and did not responded to Sertraline at dose 100-150mg/day
2. Olanazapine was additional treatment , start 2.5mg/day at first monththen 5 mg/day for last two months of study  3. Treatment response was assessed using the Yale-Brown Obsessive- Compulsive Scale (YBOCS) at end of each months of study 16 of 20 patients respond to the olanzapine augmented sertraline therapy . The mean baseline YBOCS score of 32.75 dropped to a mean of 21.75 at endpoint for male with reduction 12.81% from baseline. While in female, the mean baseline YBOCS score of 33.83 dropped to a
mean of 21.67 at endpoint with reduction 17.06% from baseline. Treatment-refractory OCD Patients may benefit from addition of olanzapine to ongoing SSRI therapy.